-
1
-
-
84961785639
-
-
Centers for Disease Control and Prevention. National chronic kidney disease fact sheet 2014. 2014. Accessed Dec 8, 2015
-
Centers for Disease Control and Prevention. National chronic kidney disease fact sheet 2014. 2014. http://www.cdc.gov/diabetes/pubs/pdf/kidney_Factsheet.pdf. Accessed Dec 8, 2015.
-
-
-
-
2
-
-
84874644599
-
clinical practice guideline for the evaluation and management of chronic kidney disease
-
KDIGO. clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2012;2013(3):1–150.
-
(2012)
Kidney Int
, vol.2013
, Issue.3
, pp. 1-150
-
-
KDIGO1
-
3
-
-
85013870239
-
US Renal Data System 2014 Annual Data Report: epidemiology of Kidney Disease in the United States
-
Saran R, Li Y, Robinson B, et al. US Renal Data System 2014 Annual Data Report: epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2015;65:A7.
-
(2015)
Am J Kidney Dis
, vol.65
, pp. A7
-
-
Saran, R.1
Li, Y.2
Robinson, B.3
-
4
-
-
84903843914
-
Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties
-
COI: 1:CAS:528:DC%2BC2cXhtFensLvK, PID: 24322578
-
Arnouts P, Bolignano D, Nistor I, et al. Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties. Nephrol Dial Transplant. 2014;29:1284–300.
-
(2014)
Nephrol Dial Transplant
, vol.29
, pp. 1284-1300
-
-
Arnouts, P.1
Bolignano, D.2
Nistor, I.3
-
5
-
-
72049116346
-
Measured GFR as a confirmatory test for estimated GFR
-
PID: 19833901
-
Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol. 2009;20:2305–13.
-
(2009)
J Am Soc Nephrol
, vol.20
, pp. 2305-2313
-
-
Stevens, L.A.1
Levey, A.S.2
-
6
-
-
82055189944
-
Estimating glomerular filtration rate in diabetes using serum cystatin C
-
PID: 21611078
-
Macisaac RJ, Premaratne E, Jerums G. Estimating glomerular filtration rate in diabetes using serum cystatin C. Clin Biochem Rev. 2011;32:61–7.
-
(2011)
Clin Biochem Rev.
, vol.32
, pp. 61-67
-
-
Macisaac, R.J.1
Premaratne, E.2
Jerums, G.3
-
7
-
-
84883247995
-
Update on cystatin C: incorporation into clinical practice
-
COI: 1:CAS:528:DC%2BC3sXosVOhtbc%3D, PID: 23701892
-
Shlipak MG, Mattes MD, Peralta CA. Update on cystatin C: incorporation into clinical practice. Am J Kidney Dis. 2013;62:595–603.
-
(2013)
Am J Kidney Dis
, vol.62
, pp. 595-603
-
-
Shlipak, M.G.1
Mattes, M.D.2
Peralta, C.A.3
-
8
-
-
80051554197
-
Relative performance of the MDRD and CKD-EPI equations for estimating glomerular filtration rate among patients with varied clinical presentations
-
PID: 21737852
-
Murata K, Baumann NA, Saenger AK, Larson TS, Rule AD, Lieske JC. Relative performance of the MDRD and CKD-EPI equations for estimating glomerular filtration rate among patients with varied clinical presentations. Clin J Am Soc Nephrol. 2011;6:1963–72.
-
(2011)
Clin J Am Soc Nephrol.
, vol.6
, pp. 1963-1972
-
-
Murata, K.1
Baumann, N.A.2
Saenger, A.K.3
Larson, T.S.4
Rule, A.D.5
Lieske, J.C.6
-
9
-
-
84883424004
-
Cystatin C versus creatinine in determining risk based on kidney function
-
COI: 1:CAS:528:DC%2BC3sXhsVegsb3I, PID: 24004120
-
Shlipak MG, Matsushita K, Arnlov J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369:932–43.
-
(2013)
N Engl J Med
, vol.369
, pp. 932-943
-
-
Shlipak, M.G.1
Matsushita, K.2
Arnlov, J.3
-
10
-
-
39449112419
-
Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD
-
COI: 1:CAS:528:DC%2BD1cXktFegtL8%3D, PID: 18295055
-
Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008;51:395–406.
-
(2008)
Am J Kidney Dis
, vol.51
, pp. 395-406
-
-
Stevens, L.A.1
Coresh, J.2
Schmid, C.H.3
-
11
-
-
84859317513
-
Established and emerging markers of kidney function
-
COI: 1:CAS:528:DC%2BC38XlsVCmsrc%3D, PID: 22311920
-
Ferguson MA, Waikar SS. Established and emerging markers of kidney function. Clin Chem. 2012;58:680–9.
-
(2012)
Clin Chem
, vol.58
, pp. 680-689
-
-
Ferguson, M.A.1
Waikar, S.S.2
-
12
-
-
61349147106
-
Factors other than glomerular filtration rate affect serum cystatin C levels
-
COI: 1:CAS:528:DC%2BD1MXisVSnsLc%3D, PID: 19119287
-
Stevens LA, Schmid CH, Greene T, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75:652–60.
-
(2009)
Kidney Int
, vol.75
, pp. 652-660
-
-
Stevens, L.A.1
Schmid, C.H.2
Greene, T.3
-
13
-
-
84879410354
-
Comparison of serum cystatin C, serum creatinine, measured GFR, and estimated GFR to assess the risk of kidney failure in American Indians with diabetic nephropathy
-
COI: 1:CAS:528:DC%2BC3sXhtF2lsLk%3D, PID: 23347458
-
Pavkov ME, Knowler WC, Hanson RL, et al. Comparison of serum cystatin C, serum creatinine, measured GFR, and estimated GFR to assess the risk of kidney failure in American Indians with diabetic nephropathy. Am J Kidney Dis. 2013;62:33–41.
-
(2013)
Am J Kidney Dis
, vol.62
, pp. 33-41
-
-
Pavkov, M.E.1
Knowler, W.C.2
Hanson, R.L.3
-
14
-
-
84864283226
-
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
-
COI: 1:CAS:528:DC%2BC38XhtVOmtLjM, PID: 22310849
-
Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495–502.
-
(2012)
Nat Rev Endocrinol.
, vol.8
, pp. 495-502
-
-
Ferrannini, E.1
Solini, A.2
-
15
-
-
84897394040
-
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
-
COI: 1:CAS:528:DC%2BC3sXhsFequr3L, PID: 24067431
-
Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–71.
-
(2014)
Kidney Int
, vol.85
, pp. 962-971
-
-
Kohan, D.E.1
Fioretto, P.2
Tang, W.3
List, J.F.4
-
16
-
-
84899961819
-
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
-
COI: 1:CAS:528:DC%2BC2cXnslaqsbw%3D, PID: 24795251
-
Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369–84.
-
(2014)
Lancet Diabetes Endocrinol.
, vol.2
, pp. 369-384
-
-
Barnett, A.H.1
Mithal, A.2
Manassie, J.3
-
17
-
-
84876311251
-
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
-
COI: 1:CAS:528:DC%2BC3sXlvVenu7c%3D, PID: 23464594
-
Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463–73.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 463-473
-
-
Yale, J.F.1
Bakris, G.2
Cariou, B.3
-
18
-
-
84961855103
-
NJ, and Wilmington
-
® (dapagliflozin). Full Prescribing Information, Bristol-Myers Squibb and AstraZeneca, Princeton, NJ, and Wilmington, DE; 2014.
-
(2014)
DE
-
-
-
19
-
-
77956921439
-
Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial
-
PID: 20566676
-
Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217–24.
-
(2010)
Diabetes Care
, vol.33
, pp. 2217-2224
-
-
Ferrannini, E.1
Ramos, S.J.2
Salsali, A.3
Tang, W.4
List, J.F.5
-
20
-
-
84860218907
-
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
-
COI: 1:CAS:528:DC%2BC38XotlSmsL0%3D, PID: 22413962
-
Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66:446–56.
-
(2012)
Int J Clin Pract
, vol.66
, pp. 446-456
-
-
Henry, R.R.1
Murray, A.V.2
Marmolejo, M.H.3
Hennicken, D.4
Ptaszynska, A.5
List, J.F.6
-
21
-
-
77953857048
-
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
-
COI: 1:CAS:528:DC%2BC3cXotVagtro%3D, PID: 20609968
-
Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223–33.
-
(2010)
Lancet
, vol.375
, pp. 2223-2233
-
-
Bailey, C.J.1
Gross, J.L.2
Pieters, A.3
Bastien, A.4
List, J.F.5
-
22
-
-
84858020943
-
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin
-
COI: 1:CAS:528:DC%2BC38Xkt1yms78%3D, PID: 22238392
-
Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–31.
-
(2012)
J Clin Endocrinol Metab
, vol.97
, pp. 1020-1031
-
-
Bolinder, J.1
Ljunggren, O.2
Kullberg, J.3
-
23
-
-
80052524011
-
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
-
COI: 1:CAS:528:DC%2BC3MXhtlCnsb3L, PID: 21672123
-
Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13:928–38.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 928-938
-
-
Strojek, K.1
Yoon, K.H.2
Hruba, V.3
Elze, M.4
Langkilde, A.M.5
Parikh, S.6
-
24
-
-
84896701131
-
Hardy E, Sugg J, Parikh S, For the Study 10 Group. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study
-
Jabbour SA, Hardy E, Sugg J, Parikh S, For the Study 10 Group. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37:740–50.
-
(2014)
Diabetes Care
, vol.37
, pp. 740-750
-
-
-
25
-
-
84858323889
-
Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial
-
PID: 22431673
-
Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405–15.
-
(2012)
Ann Intern Med
, vol.156
, pp. 405-415
-
-
Wilding, J.P.1
Woo, V.2
Soler, N.G.3
-
26
-
-
84904466033
-
Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension
-
PID: 24890683
-
Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014;62:1252–62.
-
(2014)
J Am Geriatr Soc
, vol.62
, pp. 1252-1262
-
-
Leiter, L.A.1
Cefalu, W.T.2
de Bruin, T.W.3
Gause-Nilsson, I.4
Sugg, J.5
Parikh, S.J.6
-
27
-
-
84945175811
-
Dapagliflozin’s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension
-
COI: 1:CAS:528:DC%2BC2MXhs1Wiu7fL, PID: 25852208
-
Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin’s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care. 2015;38:1218–27.
-
(2015)
Diabetes Care
, vol.38
, pp. 1218-1227
-
-
Cefalu, W.T.1
Leiter, L.A.2
de Bruin, T.W.3
Gause-Nilsson, I.4
Sugg, J.5
Parikh, S.J.6
-
28
-
-
33747120659
-
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate
-
COI: 1:CAS:528:DC%2BD28XpsFejtbo%3D, PID: 16908915
-
Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–54.
-
(2006)
Ann Intern Med
, vol.145
, pp. 247-254
-
-
Levey, A.S.1
Coresh, J.2
Greene, T.3
-
29
-
-
84920025605
-
Metformin in patients with type 2 diabetes and kidney disease: a systematic review
-
PID: 25536258
-
Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312:2668–75.
-
(2014)
JAMA
, vol.312
, pp. 2668-2675
-
-
Inzucchi, S.E.1
Lipska, K.J.2
Mayo, H.3
Bailey, C.J.4
McGuire, D.K.5
-
30
-
-
84874768238
-
Creatinine-or cystatin C-based equations to estimate glomerular filtration in the general population: impact on the epidemiology of chronic kidney disease
-
COI: 1:CAS:528:DC%2BC3sXnt1aqurg%3D, PID: 23496839
-
Delanaye P, Cavalier E, Moranne O, Lutteri L, Krzesinski JM, Bruyere O. Creatinine-or cystatin C-based equations to estimate glomerular filtration in the general population: impact on the epidemiology of chronic kidney disease. BMC Nephrol. 2013;14:57.
-
(2013)
BMC Nephrol.
, vol.14
, pp. 57
-
-
Delanaye, P.1
Cavalier, E.2
Moranne, O.3
Lutteri, L.4
Krzesinski, J.M.5
Bruyere, O.6
-
31
-
-
0036329067
-
Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis
-
COI: 1:CAS:528:DC%2BD38XmsF2rsb8%3D, PID: 12148093
-
Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221–6.
-
(2002)
Am J Kidney Dis
, vol.40
, pp. 221-226
-
-
Dharnidharka, V.R.1
Kwon, C.2
Stevens, G.3
-
32
-
-
78651381594
-
Cystatin C identifies chronic kidney disease patients at higher risk for complications
-
PID: 21164029
-
Peralta CA, Katz R, Sarnak MJ, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol. 2011;22:147–55.
-
(2011)
J Am Soc Nephrol
, vol.22
, pp. 147-155
-
-
Peralta, C.A.1
Katz, R.2
Sarnak, M.J.3
-
33
-
-
0042167366
-
Performance of serum cystatin-C versus serum creatinine in subjects with type 1 diabetes
-
PID: 12663624
-
Buysschaert M, Joudi I, Wallemacq P, Hermans MP. Performance of serum cystatin-C versus serum creatinine in subjects with type 1 diabetes. Diabetes Care. 2003;26:1320.
-
(2003)
Diabetes Care
, vol.26
, pp. 1320
-
-
Buysschaert, M.1
Joudi, I.2
Wallemacq, P.3
Hermans, M.P.4
-
34
-
-
9644259120
-
Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy
-
COI: 1:CAS:528:DC%2BD2MXisV2qsg%3D%3D, PID: 15554952
-
Christensson AG, Grubb AO, Nilsson JA, Norrgren K, Sterner G, Sundkvist G. Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy. J Intern Med. 2004;256:510–8.
-
(2004)
J Intern Med
, vol.256
, pp. 510-518
-
-
Christensson, A.G.1
Grubb, A.O.2
Nilsson, J.A.3
Norrgren, K.4
Sterner, G.5
Sundkvist, G.6
-
35
-
-
84867367190
-
Serum concentration of cystatin C and risk of end-stage renal disease in diabetes
-
COI: 1:CAS:528:DC%2BC38XhvFShs7bM, PID: 22851596
-
Krolewski AS, Warram JH, Forsblom C, et al. Serum concentration of cystatin C and risk of end-stage renal disease in diabetes. Diabetes Care. 2012;35:2311–6.
-
(2012)
Diabetes Care
, vol.35
, pp. 2311-2316
-
-
Krolewski, A.S.1
Warram, J.H.2
Forsblom, C.3
-
36
-
-
84897910668
-
Cystatin C- and creatinine-based estimated glomerular filtration rate, vascular disease, and mortality in persons with diabetes in the U.S
-
COI: 1:CAS:528:DC%2BC2cXosVSltL4%3D, PID: 24271191
-
Tsai CW, Grams ME, Inker LA, Coresh J, Selvin E. Cystatin C- and creatinine-based estimated glomerular filtration rate, vascular disease, and mortality in persons with diabetes in the U.S. Diabetes Care. 2014;37:1002–8.
-
(2014)
Diabetes Care
, vol.37
, pp. 1002-1008
-
-
Tsai, C.W.1
Grams, M.E.2
Inker, L.A.3
Coresh, J.4
Selvin, E.5
-
37
-
-
84862097605
-
Clinical utility of creatinine- and cystatin C-based definition of renal function for risk prediction of primary cardiovascular events in patients with diabetes
-
PID: 22338108
-
Schottker B, Herder C, Muller H, Brenner H, Rothenbacher D. Clinical utility of creatinine- and cystatin C-based definition of renal function for risk prediction of primary cardiovascular events in patients with diabetes. Diabetes Care. 2012;35:879–86.
-
(2012)
Diabetes Care
, vol.35
, pp. 879-886
-
-
Schottker, B.1
Herder, C.2
Muller, H.3
Brenner, H.4
Rothenbacher, D.5
-
38
-
-
70349656626
-
Cystatin C, albuminuria, and mortality among older adults with diabetes
-
PID: 19587367
-
de Boer IH, Katz R, Cao JJ, et al. Cystatin C, albuminuria, and mortality among older adults with diabetes. Diabetes Care. 2009;32:1833–8.
-
(2009)
Diabetes Care
, vol.32
, pp. 1833-1838
-
-
de Boer, I.H.1
Katz, R.2
Cao, J.J.3
-
39
-
-
84863524855
-
Estimating glomerular filtration rate from serum creatinine and cystatin C
-
COI: 1:CAS:528:DC%2BC38XhtVOqs7bN, PID: 22762315
-
Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20–9.
-
(2012)
N Engl J Med
, vol.367
, pp. 20-29
-
-
Inker, L.A.1
Schmid, C.H.2
Tighiouart, H.3
-
40
-
-
84883799810
-
Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin
-
PID: 23806570
-
Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:479–84.
-
(2013)
J Diabetes Complications
, vol.27
, pp. 479-484
-
-
Johnsson, K.M.1
Ptaszynska, A.2
Schmitz, B.3
Sugg, J.4
Parikh, S.J.5
List, J.F.6
|